Background The emergence of drug resistant tuberculosis poses a serious concern globally and researchers are in rigorous search for new medicines to fight against these dreadful bacteria. varied compounds (GlmU inhibitors) taken from PubChem BioAssay (AID 1376). These inhibitors were docked in the active site of the C-terminal website of GlmU protein (2OI6) using the AutoDock. A QSAR model was developed using docking energies as descriptors and accomplished maximum correlation of 0.35/0.12 (r/r2) between actual and predicted pIC50. Second of all, QSAR models were developed using molecular descriptors determined using various software packages and achieved maximum correlation of 0.77/0.60 (r/r2). Finally, cross models were developed using various types of descriptors and accomplished high correlation of 0.83/0.70 (r/r2) between predicted and actual pIC50. It was observed that some molecular descriptors used in this study had high correlation with pIC50. We screened chemical libraries using models developed with this study and expected 40 potential GlmU inhibitors. These inhibitors could be used to develop medicines against Mycobacterium tuberculosis. Summary These results demonstrate that docking energies can be used as descriptors for developing QSAR models. The current work suggests that docking energies centered descriptors could be used along with popular molecular descriptors for predicting inhibitory activity (IC50) of molecules against GlmU. Based on this study an open resource Rabbit Polyclonal to Cox1 platform, http://crdd.osdd.net/raghava/gdoq, has been developed for predicting inhibitors GlmU. Background Antibiotic resistance has become a major hurdle to conquer bacterial diseases and thus there is always a need to find new drug focuses on or inhibitors or both. At present very few medicines are available in the market for treatment of M. tuberculosis illness as development of drug-resistant strains have resulted in little efficacy and some of them have shown undesired side-effects in sponsor . Studies suggest that the prevalence of Multi Drug Resistant tuberculosis (MDR-TB) ranged from 6.7% for three medicines to 34% for four medicines and has 219989-84-1 IC50 caused an annual loss of around $4 – $5 billion [2-5]. Keeping in mind the rapidly changing pathogenesis of this lethal micro-organism, recognition of novel inhibitors for recently discovered targets has become pressing need of the hour. GlmU is definitely one such target which is essential for the survival of the pathogen [6,7]. Recent studies within the Mycobacterial proteome using in-silico analysis suggested GlmU to be a potential drug target . This protein is definitely a bi-functional enzyme that catalyzes a two methods reaction. In the beginning, catalytic conversion of glucosamine-1-phosphate to N-acetyl-glucosamine-1-phosphate takes place in the C-terminal website followed by conversion of N-acetyl-glucosamine-1-phosphate to UDP-GluNAc in the N-terminal website [9,10]. Though the second step is present in prokaryotes as well as in humans, the first step is present only in prokaryotes . The absence of the first step in human makes it suitable for developing non-toxic inhibitors. The three dimensional structure of the GlmU enzyme has been reported from Escherichia coli, Mycobacterium tuberculosis, Streptococcus pneumoniae, Haemophilus influenzae, Yersinia pestis in apo and holo-forms [11-14]. These constructions 219989-84-1 IC50 have missing coordinates for the C-terminal intrinsically disordered areas. The recognition of inhibitors using experimental techniques is an expensive and tedious job. Thus, there is need to develop theoretical models for predicting inhibitors against a potential target. In the past, a number of models has been developed using QSAR and docking [12-17] for the recognition of novel inhibitors against 219989-84-1 IC50 different bacterial focuses on. Except KiDoQ  and CDD  none of them is definitely freely available to the medical community. KiDoQ is based on prediction of binding affinity against Dihydrodipicolinate synthase (DHDPS) enzyme of E.coli while CDD is a collection of compounds and predictive models against M.tb. It is important that newly developed models for predicting inhibitors should be made available in the public website, in order to aid researchers in discovering new medicines against diseases of the poor. In this study, a systematic attempt has been made to address these issues. Firstly, we developed QSAR models using docking energies as molecular descriptors. Second of all, QSAR models were developed using popular molecular descriptors determined using numerous freeware and commercial software packages. Thirdly, hybrid versions were created using docking energy structured descriptors and widely used molecular descriptors. Finally, an internet server continues to be implemented using the very best versions developed within this research, hence offering 219989-84-1 IC50 an open supply platform towards the technological community for finding new medications against bacterial focus on GlmU protein. Strategies Data established We retrieved 125 GlmU inhibitors from PubChem Bioassay Help-1376 [20,21] with known IC50 beliefs against M.tuberculosis GlmU. These inhibitors display an array of activity (1-9999 M) and structural variety (find clustering at 70% in Extra file-1). There have been mistakes in 219989-84-1 IC50 calculating descriptors for 4 substances and hence a lower group of 119 substances was considered for even more evaluation. After docking these 119.